Manipulation of the Th1/Th2 Cell Balance: An Approach to Treat Human Autoimmune Diseases?

References

• Mosmann T. R., Cherwinski H., Bond M. W., Giedlin M. A., Coffmann R. L. Two types of murine helper T cell clone. I. Definition according to profile of lymphokine activities and secreted proteins. J. Immunol. 1986; 136: 2348–2357
   PubMed Web of Science ®Google Scholar
• Del Prete G., De Carli M., Mastromauro C., Biagiotti R., Macchia D., Falagiani P., et al. Purified protein derivative of mycobacterium tuberculosis and secretory-secretory antigen(s) of toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J. Clin. Invest. 1991; 88: 346–350
   PubMed Web of Science ®Google Scholar
• Romagnani S. Human TH1 and TH2: doubt no more. Immunol. Today 1991; 12: 256–257
   PubMedGoogle Scholar
• Erard F., Wild M.-T., Garcia-Sanz J. A., Le Gros G. Switch of CD8 T cells to noncytolytic CD8-CD4- cells that make TH2 cytokines and help B cells. Science 1993; 260: 1802–1805
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin 12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 1995; 13: 251–276
   PubMed Web of Science ®Google Scholar
• Paul W. E., Seder R. A. Lymphocytes responses and cytokines. Cell 1994; 76: 241–251
   PubMed Web of Science ®Google Scholar
• Nanda N. K., Sercarz E. E., Hsu D-H., Kronenberg M. A unique pattern of lymphokine synthesis is a characteristic of certain antigen-specific suppressor T cell clones. Int. Immunol. 1994; 6: 731–737
   PubMed Web of Science ®Google Scholar
• Kelso A., Groves P., Troutt A. B., Francis K. Evidence for the stochastic acquisition of cytokine profile by CD4+ T cells activated in a T helper type 2-like response in vivo. Eur. J. Immunol. 1995; 25: 1168–1175
   PubMed Web of Science ®Google Scholar
• Kelso A. Th1 and Th2 subsets: paradigms lost?. Immunol Today 1995; 16: 374–379
   PubMedGoogle Scholar
• Pernis A., Gupta S., Gollob K. J., Garfein E., Coffman R. L., Schindler C., et al. Lack of interferon γ receptor β chain and the prevention of interferon γ signaling in Th1 cells. Science 1995; 269: 245–247
   PubMed Web of Science ®Google Scholar
• Bach E. A., Szabo S., Dighe A. S., Ashkenazi A., Aguet M., Murphy K. M., et al. Ligand-induced auto-regulation of IFN-γ receptor β chain expression in T helper cell subsets. Science 1995; 270: 1215–1218
   PubMed Web of Science ®Google Scholar
• Szabo S. J., Jacobson A. G., Gubler U., Murphy K. M. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 1995; 2: 665–675
   PubMed Web of Science ®Google Scholar
• Jacobson N. G., Szabo S. J., Gueler M. L., Gorham J. D., Murphy K. M. Regulation of interleukin-12 signal transduction during T helper phenotype development. Res. Immunol. 1995; 146
   PubMedGoogle Scholar
• Hsieh C.-S., Macatonia S. E., Tripp C. S., Wolf S. F., O'Garra A., Murphy K. M. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547–549
   PubMed Web of Science ®Google Scholar
• Manetti R., Parronchi P., Giudizi M. G., Piccinni M.-P., Maggi E., Trinchieri G., et al. Natural killer cell stimulatory factor (interleukin 12, IL-12) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 1993; 177: 1199–1204
   PubMed Web of Science ®Google Scholar
• Afonso L. C. C., Scharton T. M., Vieira L. Q., Wysocka M., Trinchieri Scott P. The adjuvant effect of interleukin-12 in a vaccine against. Leishmania major Science 1994; 263: 235–237
   Google Scholar
• Kiniwa M., Gately M., Gubler U., Chizzonite R., Fargeas C., Delespesse G. Recombinant interleukin-12 suppresses the synthesis of IgE by inter-leukin-4 stimulated human lymphocytes. J. Clin. Invest. 1992; 90: 262–266
   PubMed Web of Science ®Google Scholar
• Schmitt E., Hoehn P., Huels C., Goedert S., Palm N., Ruede E., et al. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-y and is inhibited by transforming growth factor-β. Eur. J. Immunol. 1994; 24: 793–798
   PubMed Web of Science ®Google Scholar
• Gajewski T. F., Fitch F. W. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J. Immunol. 1988; 140: 4245–4253
   PubMed Web of Science ®Google Scholar
• Moore K., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T. R. Interleukin-10. Annu. Rev. Immunol. 1993; 11: 165–190
   PubMed Web of Science ®Google Scholar
• D'Andrea A., Aste-Amezaga M., Valiante N. M., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 1993; 178: 1041–1048
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R., Figdor C. G., Huijbens R., Mohan-Peterson S., Bennett B., Culpepper J., et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-γ or IL-10. J. Immunol. 1993; 151: 6370–6381
   PubMed Web of Science ®Google Scholar
• Powrie F., Coffmann R. L. Cytokine regulation of T cell function: potential for therapeutic intervention. Immunol. Today 1993; 14: 270–274
   PubMedGoogle Scholar
• O'Garra A., Murphy K. T-cell subsets in autoimmunity. Curr. Opin. Immunol. 1993; 5: 880–886
   PubMed Web of Science ®Google Scholar
• Liblau R. S., Singer S. M., McDevitt H. O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 1995; 16: 34–38
   PubMedGoogle Scholar
• Trembleau S., Germann T., Gately M. K., Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol. Today 1995; 16: 383–386
   PubMedGoogle Scholar
• Ando D. G., Clayton J., Kong D., Urban J. L., Sercarz E. E. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th1 lymphokine subtype. Cell Immunol. 1989; 124: 132–143
   PubMed Web of Science ®Google Scholar
• Haskins K., McDuffie M. Acceleration of diabetes in young NOD mice with a CD4+ islet specific T cell clone. Science 1990; 249: 1433–1436
   PubMed Web of Science ®Google Scholar
• Bergman B., Haskins K. Islet-specific T-cell clones from the NOD mouse respond to beta-granule antigen. Diabetes 1994; 43: 197–203
   PubMed Web of Science ®Google Scholar
• Katz J. D., Benoist C., Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268: 1185–1188
   PubMed Web of Science ®Google Scholar
• Yang X-D., Tisch R., Singer S. M., Cao Z. A., Liblau R. S., Schreiber R. D., et al. Effect of tumor necrosis factor a on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J. Exp. Med. 1994; 180: 995–1004
   PubMed Web of Science ®Google Scholar
• Wogesen L., Lee M.-S., Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J. Exp. Med. 1994; 179: 1379–1384
   PubMed Web of Science ®Google Scholar
• Anderson J. T., Cornelius J. G., Jarpe A. J., Winter W. E., Peck A. B. Insulin-dependent diabetes in the NOD mouse model. II. Beta cell destruction in autoimmune diabetes is a Th2 and not a Th1 mediated event. Autoimmunity 1993; 15: 113–122
   PubMed Web of Science ®Google Scholar
• Akhtar I., Gold J. P., Pan L-Y., Ferrara J. L., Yang X-D., Kim J. I., et al. CD4+ β islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 1995; 182: 87–97
   PubMed Web of Science ®Google Scholar
• Rapoport M. J., Jaramillo A., Zipris D., Lazarus A. H., Serreze D. V., Leiter E. H., et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J. Exp. Med. 1993; 178: 87–99
   PubMed Web of Science ®Google Scholar
• Pennline K. J., Roquegaffney E., Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol 1994; 71: 169–175
   PubMedGoogle Scholar
• Fowell D., Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J. Exp. Med. 1993; 177: 627–636
   PubMed Web of Science ®Google Scholar
• Scott B., Liblau R., Degermann S., Marconi L. A., Ogata L., Caton A. J., et al. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1994; 1: 1–20
   Web of Science ®Google Scholar
• Racke M. K., Bonomo A., Scott D. E., Cannella B., Levine A., Raine C. S., et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 1994; 180: 1961–1966
   PubMed Web of Science ®Google Scholar
• Allen J. B., Wong H. L., Costa G. L., Bienkowski M. J., Wahl S. M. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J. Immunol. 1993; 151: 4344–4351
   PubMed Web of Science ®Google Scholar
• van der Veen R. C., Stohlman S. A. Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity: relative roles of interleukin (IL)-4 and IL-10. J. Neuroimmunol 1993; 48: 213–220
   PubMed Web of Science ®Google Scholar
• Khoury S. J., Hancock W. W., Weiner H. L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interlukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 1992; 176: 1355–1364
   PubMed Web of Science ®Google Scholar
• Healey D., Ozegbe P., Arden S., Chandler P., Hutton J., Cooke A. In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice. J. Clin. Invest. 1995; 95: 2979–2985
   PubMed Web of Science ®Google Scholar
• Moritani M., Yoshimoto K., Tashiro F., Hashimoto C., Miyazaki J., Li S., et al. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabete in non-obese diabetic mice. Int. Immunol. 1994; 6: 1927–1936
   PubMed Web of Science ®Google Scholar
• De Carli M., D'Elios M., Mariotti S., Marcocci C., Pinchera A., Ricci M., et al. Cytolytic T cells with Th1-like cytokine profile predominate in retrorbital lymphocytic infiltrates of Graves' ophthalmopathy. J. Clin. Endocrinol. Metab. 1993; 77: 1120–1124
   PubMed Web of Science ®Google Scholar
• Brod S. A., Benjamin D., Hafler D. A. Restricted T cell expression of IL-2, IFN-γ mRNA in human inflammatory disease. J. Immunol. 1991; 147: 810–815
   PubMed Web of Science ®Google Scholar
• Foulis A. K., McGill M., Farquahrson M. A. Insulitis in type I (insulin-dependent) diabetes mellitus in man. Macrophages, lymphocytes and interferon-γ-containing cells. J. Pathol. 1991; 165: 97–103
   PubMed Web of Science ®Google Scholar
• Miltenburg A. M., van Laar J. M., de Kuiper R., Daha M. R., Breed veld F. C. T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand. J. Immunol. 1992; 35: 603–610
   PubMed Web of Science ®Google Scholar
• De Carli M., D'Elios M. M., Zancuoghi G., Ramagnani S., Del Prete G. Human TH1 and TH2 cells: functional properties, regulation of development and role in autoimmunity. Autoimmunity 1994; 18: 301–308
   PubMedGoogle Scholar
• Simon A. K., Seipelt E., Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc. Natl Acad. Sci. USA 1994; 91: 8562–8566
   PubMed Web of Science ®Google Scholar
• Romagnani S. Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 1994; 12: 227–257
   PubMed Web of Science ®Google Scholar
• Constant S., Pfeiffer C., Woodard A., Pasqualini T., Bottomly K. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. J. Exp. Med. 1995; 182: 1591–1596
   PubMed Web of Science ®Google Scholar
• Hosken N. A., Shibuya K., Heath A. W., Murphy K. M., O'Garra A. The effect of antigen dose on CD4+ helper cell phenotype development in a T cell receptor-αβ-transgenic model. J. Exp. Med. 1995; 182: 1579–1584
   PubMed Web of Science ®Google Scholar
• Burstein H. J., Shea C. M., Abbas A. K. Aqueous antigens induce in vivo tolerance selectively in IL-2-and IFN-γ-producing (Th1) cells. J. Immunol. 1992; 148: 3687–3691
   PubMed Web of Science ®Google Scholar
• De Wit D., Van Mechelen M., Ryelandt M., Figueiredo A. C., Abramowicz D., Goldman M., et al. The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes. J. Exp. Med. 1992; 175: 9–14
   PubMed Web of Science ®Google Scholar
• Guéry J-C., Galbiati F., Smiroldo S., Adorini L. Selective development of Th2 cells induced by continuous administration of low dose soluble proteins to normal and β2-microglobulin-deficient BALB/c mice. J. Exp. Med. 1996; 186: 485–497
   Google Scholar
• Yoshimoto T., Paul E. P. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 1994; 179: 1285–1295
   PubMed Web of Science ®Google Scholar
• Bendelac A., Killeen N., Littman D. L., Schwartz R. H. A subset of CD4+ thymocytes selective by MHC class I molecules. Science 1994; 263: 1774–1778
   PubMed Web of Science ®Google Scholar
• Coles M. C., Raulet D. H. Class I dependence of development of CD4+ CD8- NK1.1+ thymocytes. J. Exp. Med. 1994; 180: 395–399
   PubMed Web of Science ®Google Scholar
• Launois P., Okteki T., Swihart K., MacDonald H. R., Louis J. A. In susceptible mice, Leishmania major induce very rapid interleukin-4 production by CD4+ T cells which are NK1.1-. Eur. J. Immunol. 1995; 25: 3298–3307
   PubMed Web of Science ®Google Scholar
• Day M. J., Tse A. G. D., Puklavec M., Simmonds S. J., Mason D. W. Targeting autoantigen to B cells prevents the induction of a cell-mediated autoimmune disease in rats. J. Exp. Med. 1992; 175: 655–659
   PubMed Web of Science ®Google Scholar
• Saoudi A., Simmonds S., Huitinga I., Mason D. W. Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of autoantigen-specific T cells. J. Exp. Med. 1995; 182: 335–344
   PubMed Web of Science ®Google Scholar
• Ernon E. E., Parker D. C. Parameters of tolerance induction by antigen targeted to B lymphocytes. J. Immunol. 1993; 151: 2958–2964
   PubMed Web of Science ®Google Scholar
• Lider O., Santos L. M. B., Lee C. S. Y., Higgins D. J., Weiner H. L. Suppression of experimental autoimmune encephalomylitis by oral administration of myelin basic protein II. Suppression of disease and in vitro response is mediated by CD8 + T lymphocytes. J. Immunol. 1989; 142: 748
   PubMed Web of Science ®Google Scholar
• Miller A., Lider O., Roberts A. B., Sporn M. B., Weiner H. L. Suppressor T cells generated by oral tolerizsation to myelin basic protein suppress both in vitro, in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc. Natl Acad. Sci. USA 1992; 89: 421–425
   PubMed Web of Science ®Google Scholar
• O'Garra A., Murphy K. Role of cytokines in determining T-lymphocyte function. Curr. Opin. Immunol. 1994; 6: 458–466
   PubMed Web of Science ®Google Scholar
• Karpus W. J., Gould K. E., Swanborg R. H. CD4 + suppressor cells of autoimmune encephalomylitis respond to T cell receptor-associated determinants on effector cells by interleukin-4 secretion. Eur. J. Immunol. 1992; 22: 1757–1763
   PubMed Web of Science ®Google Scholar
• Harrison L. C. Islet cell autoantigens in insulin-dependent diabetes: Pandora's box re-visited. Immunol. Today 1992; 13: 348–352
   PubMedGoogle Scholar
• Kaufman D. L., Clare-Salzler M., Tian J., Forsthuber T., Ting G. S. P., Robinson P., et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366: 69–72
   PubMed Web of Science ®Google Scholar
• Tisch R., Yang X-D., Singer S. M., Liblau R. S., Fugger L., McDevitt H. O. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366: 72–75
   PubMed Web of Science ®Google Scholar
• Briner T., Kuo M-C., Keating K. M., Rogers B. L., Greenstein J. L. Peripheral T cell tolerance induce in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc. Natl Acad. Sci. USA 1993; 90: 7608–7612
   PubMed Web of Science ®Google Scholar
• Weiner H. L., Friedman A., Miller A., Khoury S. J., Al-Sabbagh A., Santos L., et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 1994; 12: 809–837
   PubMed Web of Science ®Google Scholar
• Chen Y., Inobe J-I., Marks R., Gonnella P., Kuchroo V. K., Weiner H. L. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995; 376: 177–180
   PubMed Web of Science ®Google Scholar
• Critchfield J. M., Racke M. K., Zuniga-Pflucker J. C., Cannella B., Raine C. S., Goverman J., et al. T cell Deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994; 263: 1139–1143
   PubMed Web of Science ®Google Scholar
• Weinberg A. D., Whitham R., Swain S. L., Morrison W. J., Wyrick G., Hoy C., et al. Transforming growth factor beta enhances the in vivo effector function and memory phenotype of antigen-specific T helper cells in experimental autoimmune encephalomylitis. J. Immunol. 1992; 148: 2109–2117
   PubMed Web of Science ®Google Scholar
• Metzler B., Wraith D. C. Inhibition of experimental autoimmune encephalitis by inhalation but not by oral administration of encephalitogenic peptide: influence of MHC binding. Int. Immunol. 1992; 5: 1159–1165
   Web of Science ®Google Scholar
• Weiner H. L., Mackin G. A., Matsui M., Orav E. J., Khoury S. J., Dawson D. M., et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321–1324
   PubMed Web of Science ®Google Scholar
• Trentham D. E., Dynesius-Trentham R. A., Orav E. J., Combitchi D., Lorenzo C., Sewell K. L., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261: 1727–1730
   PubMed Web of Science ®Google Scholar
• Pfeiffer C., Stein J., Southwood S., Ketelaar H., Setta A., Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J. Exp. Med. 1995; 181: 1569–1574
   PubMed Web of Science ®Google Scholar
• Evavold B. D., Allen P. M. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991; 252: 1308–1310
   PubMed Web of Science ®Google Scholar
• Seder R. A., Paul W. E., Davis M. M., de Fazekas B. St. Groth. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4 + T cells from T cell receptor transgenic mice. J. Exp. Med. 1992; 176: 1091–1098
   PubMed Web of Science ®Google Scholar
• Hsieh C. S., Heimberger A., Gold J., O'Garra A., Murphy K. Differential regulation of T helper phenotype development by IL-4 and IL-10 in α, β T-cell receptor transgenic system. Proc. Natl Acad. Sci. USA 1992; 89: 6065–6069
   PubMed Web of Science ®Google Scholar
• De Magistris T. M., Alexander J., Coggeshall M., Altman A., Gaeta F. C. A., Grey H. M., et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 1992; 68: 625–634
   PubMed Web of Science ®Google Scholar
• Jameson S. C., Carbone F. R., Bevan M. J. Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells. J. Exp. Med. 1993; 177: 1541–1550
   PubMed Web of Science ®Google Scholar
• Evavold B. D., Sloan-Lancaster J., Allen P. M. Tickling the TCR: selective T cell functions stimulated by altered peptide ligands. Immunol. Today 1993; 14: 602–609
   PubMedGoogle Scholar
• Wegener A. M., Letourner F., Hoeveler A., Broker T., Luton F., Malissen B. The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell 1992; 68: 83–95
   PubMed Web of Science ®Google Scholar
• Sloan-Lancaster J., Shaw A. S., Rothbard J. B., Allen P. M. Partial T cell signaling: altered phospho-ζ and lack of zap70 recruitment in APL-indcued T cell anergy. Cell 1994; 79: 913–922
   PubMed Web of Science ®Google Scholar
• Madrenas J., Wange R. L., Wang J. L., Isakov N., Samelson L. E., Germain R. N. ζ phosphorylation without zap-70 activation induced by TCR antagonists or partial agonists. Science 1995; 267: 515–518
   PubMed Web of Science ®Google Scholar
• Sloan-Lancaster J., Evavold B. D., Allen P. M. Induction of T cell anergy by altered T cell receptor ligand on live antigen-presenting cells. Nature 1993; 363: 156–159
   PubMed Web of Science ®Google Scholar
• Sloan-Lancaster J., Evavold B., Allen P. M. Th2 cell clonal energy as a consequence of partial activation. J. Exp. Med. 1994; 180: 1195–1205
   PubMed Web of Science ®Google Scholar
• Klenerman P., Rowland-Jones S., McAdam S., Edwards J., Daenke S., Lalloo D., et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 1994; 369: 403–407
   PubMed Web of Science ®Google Scholar
• Bertoletti A., Sette A., Chisari F. V., Penna A., Levrero M., De Carli M., et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369: 407–410
   PubMed Web of Science ®Google Scholar
• Franco A., Southwood S., Arrhenius T., Kucroo V. K., Grey H. M., Sette A., et al. T cell receptor antagonist peptides are effective inhibitors of experimental allergic encephalomyelitis. Eur. J. Immunol. 1994; 24: 940–946
   PubMed Web of Science ®Google Scholar
• Karin N., Mitchell D. J., Brocke S., Ling N., Steinman L. Reversal of Experimental Autoimmune Encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon y and tumor necrosis factor a production. J. Exp. Med. 1994; 18: 2227–2237
   Google Scholar
• Nicholson L. B., Greer J. M., Sobel R. A., Lees M. B., Kuchroo V. K. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995; 3: 397–405
   PubMed Web of Science ®Google Scholar
• Windhagen A., Scholz C., Hollsberg P., Fukaura H., Sette A., Hafler D. A. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995; 2: 373–380
   PubMed Web of Science ®Google Scholar
• Smilek D. E., Wraith D. C., Hodgkinson S., Dwivedy S., Steinman L., McDevitt H. O. A single amino acid change in myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 1991; 88: 9633–9637
   PubMed Web of Science ®Google Scholar
• Gautam A. M., Pearson C. I., Smilek D. E., Steinman L., McDevitt H. O. A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis. J. Exp. Med. 1992; 176: 605–609
   PubMed Web of Science ®Google Scholar
• Wauben M. H. M., Boog C. J. P., van der Zee R., Joosten L., Schlief A., van Eden W. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J. Exp. Med. 1992; 176: 667–677
   PubMed Web of Science ®Google Scholar
• Wolf S. F., Temple P. A., Kobayashi M., Young D., Dicig M., Lowe L., et al. Cloning of cDNA for natural killer stimulatory factor, a heterodimeric cytokine ith multiple biological effects on T and natural killer cells. J. Immunol. 1991; 146: 3074–3081
   PubMed Web of Science ®Google Scholar
• Gubler U., Chua A. O., Schoenhaut D. S., Dwyer C. M., McComas W., Motyka R., et al. Coexpression of two distinct genes is required to generate secreted, bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA 1991; 88: 4143–4147
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008–4027
   PubMed Web of Science ®Google Scholar
• Germann T., Gately M., Schoenhaut D. S., Lohoff M., Mattner F., Fischer S., et al. Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. Eur. J. Immunol. 1993; 23: 1762–1770
   PubMed Web of Science ®Google Scholar
• Trembleau S., Penna G., Bosi E., Mortara A., Gately M. K., Adorini L. IL-12 administration induces Th 1 cells and accelerates autoimmune diabetes in NOD mice. J. Exp. Med. 1995; 181: 817–821
   PubMed Web of Science ®Google Scholar
• Magram J., Sfarra J., Connaughton S., Faherty D., Warrier R., Carvajal D., et al. IL-12 deficient mice are defective but not devoid of type 1 cytokine responses. New York Acad. Sci. 1996, in press
   Web of Science ®Google Scholar
• Leonard J. P., Waldburger K. E., Goldman S. J. Prevention of experimental autoimmune encephalo-myelitis by antibodies against interleukin-12. J. Exp. Med. 1995; 181: 381–386
   PubMed Web of Science ®Google Scholar
• Germann T., Szeliga J., Hess H., Stoerkel S., Podlaski F. J., Gately M. K., et al. Administration of IL-12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc. Natl Acad. Sci. USA 1995; 92: 4823–4827
   PubMed Web of Science ®Google Scholar
• Neurath M. F., Fuss I., Kelsall B. L., Stueber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 1995; 182: 1281–1290
   PubMed Web of Science ®Google Scholar
• Chua A. O., Chizzonite R., Desai B. B., Truitt T. P., Nunes P., Minetti L. J., et al. Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J. Immunol. 1994; 153: 128–136
   PubMed Web of Science ®Google Scholar
• Chua A. O., Wilkinon V. L., Presky D. H., Gubler U. Cloning and characterization of a mouse IL-12 receptor β component. J. Immunol. 1995; 155: 4286–4294
   PubMed Web of Science ®Google Scholar
• Murphy E. E., Terres G., Macatonia S. E., Hsieh C-S., Mattson J., Lanier L., et al. B7 and interleukin 12 cooperate for proliferation and interferon γ production by mouse T helper clones that are unresponsive to B7 costimulation. J. Exp. Med. 1994; 180: 223–231
   PubMed Web of Science ®Google Scholar
• Ding L., Linsley P. S., Huang L. Y., Germain R. N., Shevach E. M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 1993; 151: 1224–1234
   PubMed Web of Science ®Google Scholar
• Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M. H., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 1991; 147: 3815–3622
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R., Abrams J., Bennett B., Figdor C., de Vries J. IL-10 inhibits cytokine synthesis by human monocytes; an auto-regulatory role of IL-10 produced by monocytes. J. Exp. Med. 1991; 174: 1209–1220
   PubMed Web of Science ®Google Scholar
• Bogdan C., Vodovotz Y., Nathan C. Macrophage deactivation by interleukin 10. J. Exp, Med. 1991; 174: 1549–1555
   PubMed Web of Science ®Google Scholar
• Bromberg J. S. IL-10 immunosuppression in transplantation. Curr. Opin. Immunol. 1995; 7: 639–643
   PubMed Web of Science ®Google Scholar
• Kuehn R., Loehler J., Rennick D., Rajewsky K., Mueller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263–274
   PubMed Web of Science ®Google Scholar
• Powrie F., Leach M. W., Mauze S., Menon S., Caddie L. B., Coffman R. L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994; 1: 553–562
   PubMed Web of Science ®Google Scholar
• Chatelain R., Varkila K., Coffman R. L. IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 1992; 148: 1182–1187
   PubMed Web of Science ®Google Scholar
• Sadick M. D., Heinzel F. P., Holaday B. J., Pu R. T., Dawkins R. S., Locksley R. M. Cure of murine leishmaniasis with anti-interleukin-4 monoclonal antibody. Evidence for a T cell-dependent mechanism. J. Exp. Med. 1990; 171: 115–127
   PubMed Web of Science ®Google Scholar
• Powrie F., Menon S., Coffman R. L. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol. 1993; 23: 3043–3049
   PubMed Web of Science ®Google Scholar
• Shehadeh N., Calcinaro F., Bradley B. J., Bruchlim I., Vardi P., Lafferty K. J. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 1994; 343: 706–707
   PubMed Web of Science ®Google Scholar
• Rabinovitch A., Suarez-Pinzon W. L., Sorensen O., Bleackley R. C., Power R. F. IFN-γ gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J. Immunol. 1995; 154: 4874–4882
   PubMed Web of Science ®Google Scholar
• Kingsley G., Lanchbury J., Panayi G. Immunotherapy in rheumatic disease: an idea whose time has come—or gone?. Immunol. Today 1996; 17: 9–12
   PubMedGoogle Scholar
• Keffer J., Probert L., Cazlaris H., Georgopulos S., Kaslaris E., Koussis D., et al. Transgenic mice expressing human tumor necrosis factor—a predictive genetic model of arthritis. EMBO J. 1991; 13: 4025–4031
   Google Scholar
• Williams R. O., Feldmann M., Maini R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 1992; 89: 9784–9788
   PubMed Web of Science ®Google Scholar
• Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1993; 36: 1681–1690
   PubMed Web of Science ®Google Scholar
• Haak-Frendscho M., Marsters S. A., Mordenti J., Brady S., Gillett N. A., Chen S. A., et al. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. J. Immunol. 1994; 152: 1347–1353
   PubMed Web of Science ®Google Scholar
• Baker D., Butler D., Scallon B. J., O'Neill J. K., Turk J. L., Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 1994; 24: 2040–2048
   PubMed Web of Science ®Google Scholar
• Reiner S. L., Locksley R. M. The regulation of immunity to Leishmania Major. Annu. Rev. Immunol. 1995; 13: 151–177
   PubMed Web of Science ®Google Scholar
• Heinzel F. P., Schoenhaut D. S., Rerko R. M., Rosser L. E., Gately M. K. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 1993; 177: 1505–1559
   PubMed Web of Science ®Google Scholar